Literature DB >> 30149989

Subclassification of hepatocellular adenomas: practical considerations in the implementation of the Bordeaux criteria.

Gregory C Miller1, Catherine M Campbell2, Bavahuna Manoharan3, Richard Bryant4, David Cavallucci4, Nicholas O'Rourke4, Andrew D Clouston5.   

Abstract

Hepatocellular adenomas are benign liver lesions with a risk of rupture and malignant transformation. Various molecular subgroups have been identified which appear to have characteristic morphological and immunohistochemical features. We examined the morphology and immunohistochemical profile of a series of 121 HCA from 97 patients to identify the HCA subtypes present and determine the number at risk for malignant transformation according to the World Health Organization (WHO) criteria for hepatocellular adenomas. There were 34 HNF1α inactivated HCA (28%), 61 inflammatory HCA (50%), 15 β-catenin activated HCA (12%) and 11 unclassified adenomas (9%). This proportion of cases was similar to that seen in other series utilising molecular classification. The morphological features of the adenomas were suggestive but not definite indicators of the subtypes present. Morphological features that showed overlap between the subtypes included steatosis within the lesion, a ductular reaction and focal atypia, so that immunohistochemical typing was required for accurate classification. In conclusion, immunohistochemistry is a clinically useful surrogate for identifying underlying molecular changes in the HCA subtypes.
Copyright © 2018 Royal College of Pathologists of Australasia. All rights reserved.

Entities:  

Keywords:  Liver neoplasms; adenoma; hepatocellular adenoma; immunohistochemistry; liver cell

Mesh:

Substances:

Year:  2018        PMID: 30149989     DOI: 10.1016/j.pathol.2018.05.003

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons' Perspective.

Authors:  Paulo Herman; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Vagner Birk Jeismann; Fabricio Ferreira Coelho
Journal:  J Gastrointest Surg       Date:  2020-07-14       Impact factor: 3.452

Review 2.  The impact of hepatocyte nuclear factor-1α on liver malignancies and cell stemness with metabolic consequences.

Authors:  Xue Wang; Waseem Hassan; Jing Zhao; Sahar Bakht; Yunjuan Nie; Ying Wang; Qingfeng Pang; Zhaohui Huang
Journal:  Stem Cell Res Ther       Date:  2019-11-04       Impact factor: 6.832

3.  LAPAROSCOPIC LIVER RESECTION FOR BENIGN TUMORS: THE CURRENT POSITION.

Authors:  Paulo Herman; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Vagner Birk Jeismann; Fabricio Ferreira Coelho
Journal:  Arq Bras Cir Dig       Date:  2022-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.